These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 1532407)

  • 1. Failure of recombinant interleukin-2 to augment the primary humoral response to a recombinant hepatitis B vaccine in healthy adults.
    Rose RM; Rey-Martinez J; Croteau C; Silvestri RC; Haley K; DePamphilis J; Siber GR
    J Infect Dis; 1992 Apr; 165(4):775-7. PubMed ID: 1532407
    [No Abstract]   [Full Text] [Related]  

  • 2. The immune response of low dose recombinant DNA hepatitis B vaccine in teenagers in Singapore.
    Guan R; Tay HH; Yap I; Smith R; Tan LH
    Trans R Soc Trop Med Hyg; 1990; 84(5):731-2. PubMed ID: 2148992
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunogenicity of a heat-treated recombinant DNA hepatitis B vaccine.
    Just M; Berger R
    Vaccine; 1988 Oct; 6(5):399-400. PubMed ID: 2973693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Qualitative analysis of the humoral immune response to the "a" determinant of HBs antigen after inoculation with plasma-derived or recombinant vaccine.
    Waters JA; O'Rourke SM; Richardson SC; Papaevangelou G; Thomas HC
    J Med Virol; 1987 Feb; 21(2):155-60. PubMed ID: 2434612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune response to hepatitis B vaccine in premature neonates.
    Chawareewong S; Jirapongsa A; Lokaphadhana K
    Southeast Asian J Trop Med Public Health; 1991 Mar; 22(1):39-40. PubMed ID: 1835140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Unsuccessful vaccination against hepatitis B].
    Jilg W
    Dtsch Med Wochenschr; 1990 Nov; 115(46):1773. PubMed ID: 2146107
    [No Abstract]   [Full Text] [Related]  

  • 7. Specific lymphocyte proliferative response in vitro after cDNA HBsAg immunization.
    Degrassi A; Mariani E; Roda P; Miniero R; Capelli M; Honorati MC; Astaldi A; Facchini A
    Adv Exp Med Biol; 1989; 257():237-45. PubMed ID: 2533459
    [No Abstract]   [Full Text] [Related]  

  • 8. Antibody responses to recombinant, yeast-derived hepatitis B vaccine in teenage New Zealand children.
    Milne A; Moyes CD; Allwood GK; Pearce NE; Krugman S
    N Z Med J; 1988 Feb; 101(840):67-9. PubMed ID: 2967940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immune response to recombinant anti-hepatitis-B vaccine in a group at risk].
    León A; García Marcos JA; Nash R; Asensio A; Sanz T; Mateos Lindemann M
    Enferm Infecc Microbiol Clin; 1990 Dec; 8(10):660-1. PubMed ID: 2151508
    [No Abstract]   [Full Text] [Related]  

  • 10. Hepatitis B vaccines in patients with chronic renal failure before dialysis.
    Seaworth B; Drucker J; Starling J; Drucker R; Stevens C; Hamilton J
    J Infect Dis; 1988 Feb; 157(2):332-7. PubMed ID: 2961818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant adenovirus induces antibody response to hepatitis B virus surface antigen in hamsters.
    Morin JE; Lubeck MD; Barton JE; Conley AJ; Davis AR; Hung PP
    Proc Natl Acad Sci U S A; 1987 Jul; 84(13):4626-30. PubMed ID: 2955413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of a recombinant yeast-derived hepatitis B vaccine (Engerix B) in children.
    Moyes C; Milne A
    N Z Med J; 1988 Apr; 101(843):162-4. PubMed ID: 2965799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inadequate immune response among public safety workers receiving intradermal vaccination against hepatitis B--United States, 1990-1991.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1991 Aug; 40(33):569-72. PubMed ID: 1830921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hepatitis B at an open institution for the mentally retarded. Immunogenic effect of a recombinant anti-hepatitis-B vaccine].
    García O; Bruguera M; Mayor A; Sánchez-Tapias JM; Vall O; Rodés J
    Enferm Infecc Microbiol Clin; 1990 Mar; 8(3):148-52. PubMed ID: 2151250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of recombinant yeast hepatitis B vaccine.
    Davidson M; Krugman S
    Lancet; 1985 Jan; 1(8420):108-9. PubMed ID: 2857007
    [No Abstract]   [Full Text] [Related]  

  • 16. Cellular and humoral modifications during response to HBsAg vaccine in healthy subjects: comparison between French and American vaccines.
    D'Amelio R; Matricardi PM; Di Addario A; Le Moli S; Paganelli E; Nisini R; Sirianni MC; Fattorossi A; Cherchi M; Gaetano C
    Boll Ist Sieroter Milan; 1989; 68(1):57-61. PubMed ID: 2535246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma-derived versus recombinant hepatitis B vaccines.
    Kurtz JB; Alder MJ; Mayon-White RT; Juel-Jensen BE; Rodgers TM; Babic GM
    Lancet; 1989 Feb; 1(8635):451. PubMed ID: 2563836
    [No Abstract]   [Full Text] [Related]  

  • 18. From the Centers for Disease Control. Inadequate immune response among public safety workers receiving intradermal vaccination against hepatitis B--United States, 1990-1991.
    JAMA; 1991 Sep; 266(10):1338-9. PubMed ID: 1831865
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunogenicity and safety of recombinant yeast-derived hepatitis B vaccine in haemodialysis patients.
    Fujiyama S; Yoshida K; Sato T; Shimada H; Deguchi T
    Hepatogastroenterology; 1990 Dec; 37 Suppl 2():140-4. PubMed ID: 2150664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hepatitis B vaccination in dialysis patients: reversibility of defective immune response by simultaneous administration of interleukin 2].
    Zeitz M
    Z Gastroenterol; 1990 Mar; 28(3):179-80. PubMed ID: 2140478
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.